| abstract |
The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors. Angiogenesis inhibitors are administered to regulate normal, non-transformed vascularized tissue size and/or growth by regulating its vascular compartment. Examples of tissues that can be controlled include adipose tissue, intestinal polyps, muscle (including cardiac) tissue, endometrial tissue and prostate tissue. The inhibitor is selected from the group consisting of TNP-470, angiostatin, endostatin, and thalidomide. |